ArticlePloS one2025
Phase II trial protocol of focal prostate ablation combined with androgen deprivation therapy for prostate cancer treatment.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05790213 (Phase II Trial of Focal Prostate Ablation Combined With Androgen Deprivation Therapy for Prostate Cancer Treatment), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial of Focal Prostate Ablation Combined With Androgen Deprivation Therapy for Prostate Cancer Treatment
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PCa) is one of the most commonly diagnosed cancers. Treatments for PCa with less adverse effects than whole gland interventions, such as focal therapy (FT), often involve a higher risk of PCa recurrence. Combining FT with other treatments could increase the efficacy while maintaining a low side effect profile. This study aims to determine the proportion of residual/recurrent clinically significant PCa following the combination treatment of three months of androgen deprivation therapy (ADT) and FT of the prostate, as well as the safety of this treatment regimen.
methodsThis study will be a single arm phase II trial with a recruitment goal of 57 patients with treatment naïve non-metastatic intermediate risk PCa. Patients will complete the I-PSS, SHIM, and EPIC-26 questionnaires at the screening visit. Patients will then comply with a three-month treatment course of ADT. Eight weeks after beginning ADT, patients will undergo FT of the prostate via high intensity focused ultrasound or cryoablation. Follow up visits will occur every three months for a year post FT to monitor for side effects, repeat questionnaires, perform a clinical assessment, and obtain PSA and testosterone values. Twelve months after FT, a surveillance multiparametric MRI and MRI-targeted biopsy will be performed to assess for treatment failure. DISCUSSION: The primary endpoint of this trial is to determine the proportion of men with clinically significant PCa as evaluated by a surveillance mpMRI and MRI-TB at 12-months following FT. If successful, this treatment approach could offer a new option for treatment with fewer side effects than whole gland interventions and more efficacy than FT alone. Furthermore it could inform the need for further research into multimodal treatment options for PCa. CLINICAL
trial registrationClinicalTrials.gov, NCT05790213. Registered on March 30, 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.